Leerink downgraded Synlogic to Market Perform from Outperform with a price target of $1, down from $6, following the company’s “surprising” decision to discontinue its lead program, SYNB1934 in PKU, ahead of the planned interim analysis. Synlogic is evaluating strategic options, but based on other recent examples of companies who reported similar kinds of data that fell short of expectations, the firm has low expectations that Synlogic’s programs will be acquired for further development, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYBX:
- Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
- Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
- Synlogic reports publication of prelinical, clinical data for SYNB1353
- Synlogic Provides Corporate Update and Outlook for 2024
- Synlogic provides corporate update, outlook for 2024
